Second Circuit hears Actavis anti-competition case

16-04-2015

The US Court of Appeals for the Second Circuit has heard arguments surrounding whether Actavis should be allowed to discontinue its first Alzheimer’s drug Namenda (memantine hydrochloride) to make way for an extended release version of the medicine.


US Court of Appeals for the Second Circuit, Actavis, Namenda, antitrust, Eric Schneiderman

LSIPR